Therapeutic Monoclonal Antibodies and Antibody Products, Their Optimization and Drug Design in Cancers

Therapeutic Monoclonal Antibodies and Antibody Products, Their Optimization and Drug Design in Cancers PDF

Author: Veysel Kayser

Publisher: Mdpi AG

Published: 2022-01-25

Total Pages: 298

ISBN-13: 9783036526874

DOWNLOAD EBOOK →

The book broadly deals with therapeutic monoclonal antibodies (mAbs) and various relevant topics, including different antibody formats such as Antibody-Drug Conjugates (ADC), bispecifics, nanoparticle-based mAbs and HER2+ cancers, immune checkpoint inhibitors and other closely related topics. Each paper was written by leading active research groups in their fields both from academia and industry. The book should be of interest to those scientists and researchers who develop or use biologics, biotherapeutics, biosimilars and biobetters in cancer treatment.

Innovations for Next-Generation Antibody-Drug Conjugates

Innovations for Next-Generation Antibody-Drug Conjugates PDF

Author: Marc Damelin

Publisher: Springer

Published: 2018-05-29

Total Pages: 357

ISBN-13: 3319781545

DOWNLOAD EBOOK →

Antibody-drug conjugates (ADCs) stand at the verge of a transformation. Scores of clinical programs have yielded only a few regulatory approvals, but a wave of technological innovation now empowers us to overcome past technical challenges. This volume focuses on the next generation of ADCs and the innovations that will enable them. The book inspires the future by integrating the field’s history with novel strategies and cutting-edge technologies. While the book primarily addresses ADCs for solid tumors, the last chapter explores the emerging interest in using ADCs to treat other diseases. The therapeutic rationale of ADCs is strong: to direct small molecules to the desired site of action (and away from normal tissues) by conjugation to antibodies or other targeting moieties. However, the combination of small and large molecules imposes deep complexity to lead optimization, pharmacokinetics, toxicology, analytics and manufacturing. The field has made significant advances in all of these areas by improving target selection, ADC design, manufacturing methods and clinical strategies. These innovations will inspire and educate scientists who are designing next-generation ADCs with the potential to transform the lives of patients.

Antibody-Drug Conjugates

Antibody-Drug Conjugates PDF

Author: Kenneth J. Olivier, Jr.

Publisher: John Wiley & Sons

Published: 2016-11-14

Total Pages: 474

ISBN-13: 111906080X

DOWNLOAD EBOOK →

Providing practical and proven solutions for antibody-drug conjugate (ADC) drug discovery success in oncology, this book helps readers improve the drug safety and therapeutic efficacy of ADCs to kill targeted tumor cells. • Discusses the basics, drug delivery strategies, pharmacology and toxicology, and regulatory approval strategies • Covers the conduct and design of oncology clinical trials and the use of ADCs for tumor imaging • Includes case studies of ADCs in oncology drug development • Features contributions from highly-regarded experts on the frontlines of ADC research and development

Antibody-Drug Conjugates and Immunotoxins

Antibody-Drug Conjugates and Immunotoxins PDF

Author: Gail Lewis Phillips

Publisher: Springer Science & Business Media

Published: 2012-12-13

Total Pages: 370

ISBN-13: 1461454565

DOWNLOAD EBOOK →

This volume gathers the leading research on antibody-drug conjugates and immunotoxins. Following a rigorous overview, the volume delves into focused sections on all aspects of ADCs and ITs from clinical development through to targeted therapeutic applications and the latest technologies.

Monoclonal Antibody Production

Monoclonal Antibody Production PDF

Author: National Research Council

Publisher: National Academies Press

Published: 1999-05-06

Total Pages: 74

ISBN-13: 0309173051

DOWNLOAD EBOOK →

The American Anti-Vivisection Society (AAVS) petitioned the National Institutes of Health (NIH) on April 23, 1997, to prohibit the use of animals in the production of mAb. On September 18, 1997, NIH declined to prohibit the use of mice in mAb production, stating that "the ascites method of mAb production is scientifically appropriate for some research projects and cannot be replaced." On March 26, 1998, AAVS submitted a second petition, stating that "NIH failed to provide valid scientific reasons for not supporting a proposed ban." The office of the NIH director asked the National Research Council to conduct a study of methods of producing mAb. In response to that request, the Research Council appointed the Committee on Methods of Producing Monoclonal Antibodies, to act on behalf of the Institute for Laboratory Animal Research of the Commission on Life Sciences, to conduct the study. The 11 expert members of the committee had extensive experience in biomedical research, laboratory animal medicine, animal welfare, pain research, and patient advocacy (Appendix B). The committee was asked to determine whether there was a scientific necessity for the mouse ascites method; if so, whether the method caused pain or distress; and, if so, what could be done to minimize the pain or distress. The committee was also asked to comment on available in vitro methods; to suggest what acceptable scientific rationale, if any, there was for using the mouse ascites method; and to identify regulatory requirements for the continued use of the mouse ascites method. The committee held an open data-gathering meeting during which its members summarized data bearing on those questions. A 1-day workshop (Appendix A) was attended by 34 participants, 14 of whom made formal presentations. A second meeting was held to finalize the report. The present report was written on the basis of information in the literature and information presented at the meeting and the workshop.

Therapeutic Monoclonal Antibodies

Therapeutic Monoclonal Antibodies PDF

Author: Zhiqiang An

Publisher: John Wiley & Sons

Published: 2011-09-20

Total Pages: 932

ISBN-13: 1118210263

DOWNLOAD EBOOK →

70-chapter authoritative reference that covers therapeutic monoclonal antibody discovery, development, and clinical applications while incorporating principles, experimental data, and methodologies. First book to address the discovery and development of antibody therapeutics in their entirety. Most chapters contain experimental data to illustrate the principles described in them. Authors provide detailed methodologies that readers can take away with them and use in their own laboratories.

Monoclonal Antibody-Directed Therapy

Monoclonal Antibody-Directed Therapy PDF

Author: Veysel Kayser

Publisher: Mdpi AG

Published: 2022-01-28

Total Pages: 144

ISBN-13: 9783036528731

DOWNLOAD EBOOK →

The book deals with therapeutic monoclonal antibodies (mAbs) broadly, and relevant topics such as challenges and opportunities, next-generation antibody products, Antibody-Drug-Conjugates (ADC), bispecifics, glycosylation, and T-cell engagers are covered. Each topic has been written by leading groups around the world and the book should be of interest to researchers from both academia and industry.

Antibody-Drug Conjugates and Immunotoxins

Antibody-Drug Conjugates and Immunotoxins PDF

Author: Gail Lewis Phillips

Publisher: Springer

Published: 2012-12-12

Total Pages: 378

ISBN-13: 9781461454571

DOWNLOAD EBOOK →

This volume gathers the leading research on antibody-drug conjugates and immunotoxins. Following a rigorous overview, the volume delves into focused sections on all aspects of ADCs and ITs from clinical development through to targeted therapeutic applications and the latest technologies.

Antibody-Drug Conjugates

Antibody-Drug Conjugates PDF

Author: Laurent Ducry

Publisher: Humana

Published: 2016-08-23

Total Pages: 0

ISBN-13: 9781493960262

DOWNLOAD EBOOK →

Antibody-drug conjugates (ADCs) represent a promising therapeutic approach for cancer patients by combining the antigen-targeting specificity of monoclonal antibodies (mAbs) with the cytotoxic potency of chemotherapeutic drugs. In Antibody-Drug Conjugates, expert researchers provide detailed protocols for many of the key ADC techniques necessary for working in the field. These chapters and methodologies are aimed at the key tasks necessary to identify a suitable target, properly design the mAb, the linker and the payload, as well as to conjugate them in a reproducible and scalable fashion. Written in the highly successful Methods in Molecular BiologyTM format, these detailed chapters include the kind of practical implementation advice that guarantees quality results. Authoritative and timely, Antibody-Drug Conjugates aims to further drive ADC development and thus help toward improving cancer treatments of the future.

Development of Antibody-Based Therapeutics

Development of Antibody-Based Therapeutics PDF

Author: Mohammad A. Tabrizi

Publisher: Springer

Published: 2018-09-11

Total Pages: 248

ISBN-13: 9811304963

DOWNLOAD EBOOK →

With a key focus on recent developments and advances in the field, this book provides in-depth coverage of topics fundamental to the development of targeted therapeutics. The expansion of targeted modalities in rapidly evolving therapeutic areas, such as immune-oncology, and developments with respect to combination therapies, novel technologies, and the therapeutic application of antibody-drug conjugates, are presented. Additionally, the book builds upon topics discussed in the first edition (2012) where recent innovations warrant elaboration. This, the second edition of Development of Antibody-Based Therapeutics: Translational Considerations, represents a comprehensive evaluation of progress in the field, which sits alongside the first edition to inform, in detail, professional and academic researchers, as well as graduate students.